Technology in Cancer Research & Treatment (Oct 2023)

Influence of Humoral Response Against GnRH, Generated by Immunization with a Therapeutic Vaccine Candidate on the Evolution of Patients with Castration-Sensitive Prostate Adenocarcinoma

  • Ana Cristina Campal-Espinosa PhD,
  • Jesús Arturo Junco-Barranco PhD,
  • Franklin Fuentes-Aguilar MSc,
  • Lesvia Calzada-Aguilera BSc,
  • Annia Rivacoba-Betancourt MD,
  • Ranfis Humberto Rodríguez-Bueno MD,
  • Ana Claudia Bover-Campal MD,
  • Eddy Emilio Bover-Fuentes MSc,
  • Lourdes González BSc,
  • Lourdes de Quesada MSc,
  • Allelin Alvarez BSc,
  • Hilda Elisa Garay-Pérez PhD

DOI
https://doi.org/10.1177/15330338231207318
Journal volume & issue
Vol. 22

Abstract

Read online

Background and aims A gonadotropin-releasing hormone (GnRH)-based therapeutic vaccine candidate against hormone-sensitive prostate cancer has demonstrated its safety and signs of efficacy in phase I/II trials. In this study, we characterized the isotype/subclass profiles of the anti-GnRH humoral response generated by the vaccination and analyzed its association with patients’ clinical outcomes. Methods The immunoglobulin isotypes and IgG subclasses of the antibody responses of 34 patients included in a randomized, open, prospective phase I/II clinical trial were characterized. Every patient included in the study had a diagnosis of locally advanced prostate adenocarcinoma at stages 3 and 4 and received immunization with the vaccine candidate. Additionally, serum testosterone and prostate specific antigen (PSA) concentrations, serving as indicators of tumor response, were determined. The type of anti-GnRH antibody response was correlated to the time elapsed until the first biochemical recurrence in patients and the outcome of the disease. Results All patients developed strong and prolonged anti-GnRH antibody responses, resulting in a short- to mid-term decrease in serum testosterone and PSA levels. Following immunizations, anti-GnRH antibodies of the IgM/IgG and IgG1/IgG3 subclasses were observed. Following radiotherapy, the humoral response switched to IgG (IgG1/IgG4). Patients who experienced a short-term biochemical relapse were characterized by significantly higher levels of anti-GnRH IgG titers, particularly IgG1 and IgG4 subclasses. These characteristics, along with a high response of specific IgM antibodies at the end of immunizations and the development of anti-GnRH IgA antibody responses following radiotherapy, were observed in patients whose disease progressed, compared to those with controlled disease. Conclusion The nature of the humoral response against anti-GnRH, induced by vaccination may play a key role in activating additional immunological mechanisms. Collectively, these mechanisms could contribute significantly to the regulation of tumor growth.